Examination of the sensitivity of T cells to fas ligation :Induction of allospecific apoptosis

Transplantation

Volumn 66, Issue 8, 1998, Pages 1067-1073

  O'Flaherty, Emmett ^a   Ali, Simi ^a   Pettit, Stephen J ^a   Kirby, John A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE ACTIVATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIBODIES; ANTIGENS, CD95; APOPTOSIS; DNA FRAGMENTATION; DRUG RESISTANCE; EPITOPES; FAS LIGAND PROTEIN; HUMANS; IN SITU NICK-END LABELING; INTERLEUKIN-2; ISOANTIGENS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MEMBRANE GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; T-LYMPHOCYTES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0032573042     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199810270-00017     Document Type: Article

References (44)

1. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449.
2. Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today 1997; 18: 240.
3. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for the human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233.
4. Debatin KM, Betlinger C, Bohler T, et al. Regulation of apoptosis through CD95(APO-1/Fas) receptor-ligand interaction. Biochem Soc Trans 1997; 25: 405.
5. Trauth BC, Klas C, Peters AMJ, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301.
6. Owen-Schaub LB, Shin Y, Crump WL III, Grimm EA. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol 1992; 140: 197.
7. Alderson MR, Tough TW, Davis-Smith T, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995; 181: 71.
8. Dhein J, Walczak H, Baumler C, et al. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature 1995; 373: 438.
9. 2+-independent T cell-mediated cytotoxity. J Exp Med 1993; 177: 195.
10. Klas C, Debatin KM, Jonker RR, Krammer PH. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 1993; 5: 625.
11. Watanabe-Fukunaga R, Brannan CI, Itoh N, et al. The cDNA structure, expression and chromosomal assignment of the mouse Fas antigen. J Immunol 1992; 152: 5120.
12. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995; 16: 39.
13. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 1347.
14. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189.
15. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630
16. Lau HT, Yu M, Fontana A, Stoeckert CJ. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273: 109.
17. Itoh N, Toshihide Y, Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol 1993; 151: 621.
18. Yoshino T, Kondo E, Cao L, et al. Inverse expression of Bcl-2 protein and Fas antigen in lymphoblasts in peripheral lymph nodes and activated peripheral blood T and B lymphocytes. Blood 1994; 83: 1856.
19. Mor F, Cohen IR. IL-2 rescues antigen-specific T cells from radiation or dexamethasone-induced apoptosis. J Immunol 1996; 156: 515.
20. S) gene expression. Eur J Immunol 1996; 26: 294.
21. Memon SA, Moreno MB, Petrak D, Zacharchuk CM. Bcl-2 blocks glucocorticoid- but not Fas- or activation-induced apoptosis in a T cell hybridoma. J Immunol 1995; 155: 4644.
22. Wilson JL, Cunningham AC, Kirby JA. Alloantigen presentation by B-cells: analysis of the requirement for B-cell activation. Immunol 1995; 86: 325.
23. Matzinger P. The JAM test: a simple assay for DNA fragmentation and cell death. J Immunol Methods 1991; 145: 185.
24. Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol 1993; 11: 385.
25. Sayegh MH, Watschinger B, Carpenter CB. Mechanisms of T-cell recognition of alloantigen: the role of peptides. Transplantation 1994; 57: 1295.
26. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190.
27. Bulfone-Paus S, Ungreanu D, Pohl T, et al. Interleukin-15 protects from lethal apoptosis in vivo. Nat Med 1997; 3: 1124.
28. Strasser A, Harris AW, Huang DCS, Krammer PH, Cory S. BCL-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 1995; 14: 6136.
29. Zipp F, Martin R, Lichtenfels R. Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. J Immunol 1997; 159: 2108.
30. Itoh N, Tsujimoto Y, Nagata S. Effect of Bcl-2 on Fas antigen-mediated cell death. J Immunol 1993; 151: 621.
31. Lacronique V, Mignon A, Fahre M, et al. Bcl-2 protects from lethal apoptosis induced by an anti-Fas antibody in mice. Nat Med 1996; 2: 80.
32. Salmon M, Pilling D, Borthwick NJ, et al. The progressive differentiation of primed T cells is associated with an increasing susceptibility to apoptosis. Eur J Immunol 1994; 24: 892.
33. Akbar AN, Salmon M. Cellular environments and apoptosis: tissue microenvironments control activated T-cell death. Immunol Today 1997; 18: 7233.
34. Danzer SG, Kirchner H, Rink L. Cytokine interactions in human mixed lymphocyte culture. Transplantation 1994; 57: 1638.
35. Kayagaki N, Kawasaki A, Ebata T. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182: 1777.
36. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998; 4: 31.
37. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes and soluble Fas ligand blocks the killing. J Exp Med 1997; 186: 2045.
38. Kischel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signalling complex (DISC) with the receptor. EMBO J 1995; 14: 5579.
39. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075.
40. Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 1997; 46: 317.
41. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995; 16: 569.
42. Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94: 3943.
43. Kang SM, Schneider DB, Lin Z, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3: 738.
44. Chervonsky AV, Wang Y, Wong FS, et al. The role of Fas in autoimmune diabetes. Cell 1997; 89: 17.